febrile infection-related epilepsy syndrome
Conditions
Interventions
Grouping based on whether to use Tocilizumab:None
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: (1) Age of onset =18 years old; (2) Consistent with a diagnosis of FIRES and already in chronic phase: all of the following conditions (a~c) were met, supported by condition (d) : a, as per the consensus on FIRES at the 6th Symposium on Status Epileptic and Acute Seizures. Previous health, growth and development with normal age children; b. Onset of seizures within 24 hours to 2 weeks after acute fever, with rapid deterioration and RSE; c. There is no clear evidence of infection, metabolic, immune and other related neurological diseases; d. Intractable epilepsy occurs immediately after the acute phase. The chronic phase was defined as 3 months / 90 days after the onset of seizures. (3) Tocilizumab was used for chronic treatment; (4) There was no limitation on whether tocilizumab was used in the acute stage, and no treatment with tocilizumab or anabucin was used in the chronic stage, and it was at least 1 month from the second tocilizumab or anabucin at the end of the acute stage; (5) The disease course of FIRES was less than 2 years. (6) The presence of relatively frequent seizures: the average frequency of seizures within 3 months before tozzizumab treatment was =3 times/month, and the continuous seizureless interval within 3 months before enrollment was =1 month; (7) No new immunotherapy was added within 1 month before enrollment, including glucocorticoid, propyl globule, rituximab, morpheolate, etc.; If other immunotherapy is combined with the above mentioned immunotherapy at the time of enrollment, it should be clear that the immunotherapy is in the process of gradual reduction at the time of enrollment or the dose of the immunotherapy drug has not been increased within 1 month before enrollment; (8) Patients voluntarily enrolled in the study.
Exclusion criteria
Exclusion criteria: (1) Abnormal liver function (ALT=3 times the upper limit of normal); (2) Neutropenia (neutrophil count <1.0×109/L); (3) Thrombocytopenia (platelet count <100×109/L); (4) There are active infections: there are active infections of the respiratory system, urinary system, digestive system, including active tuberculosis, hepatitis virus infection, other viruses or bacteria and other pathogenic infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective rate of reducing seizures after treatment with Tocilizumab; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse reaction;Effective rate of reducing seizures after treatment with Tocilizumab;Improvement rate of functional disability after treatment;The improvement rate of quality of life after treatment;Rate of improvement in development after treatment;Electroencephalogram period after treatment; | — |
Countries
China
Contacts
Public ContactWu Ye
Peking University First Hospital, Department of Pediatric Neurology, Children's Medical Center
Outcome results
None listed